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Abstract: Pathogen-associated molecular patterns (PAMPs) and damage-associated molecular
patterns (DAMPs) are recognized by different cellular pathogen recognition receptors (PRRs), which
are expressed on cell membrane or in the cytoplasm of cells of the innate immune system. Nucleic
acids derived from pathogens or from certain cellular conditions represent a large category of
PAMPs/DAMPs that trigger production of type I interferons (IFN-I) in addition to pro-inflammatory
cytokines, by specifically binding to intracellular Toll-like receptors or cytosolic receptors. These
cytosolic receptors, which are not related to TLRs and we call them “Toll-free” receptors, include the
RNA-sensing RIG-I like receptors (RLRs), the DNA-sensing HIN200 family, and cGAS, amongst
others. Viruses have evolved myriad strategies to evoke both host cellular and viral factors to evade
IFN-I-mediated innate immune responses, to facilitate their infection, replication, and establishment of
latency. This review outlines these “Toll-free” innate immune pathways and recent updates on their
regulation, with focus on cellular and viral factors with enzyme activities.
Keywords: PRR; cGAS; IFN-I; innate immunity

1.

Introduction

Pathogen-associated molecular patterns (PAMPs) are usually derived from invading pathogens,
and initiate rigorous innate immune responses after recognized by host germline-encoded pathogen
recognition receptors (PRRs), which are expressed on cell membrane or in the cytoplasm of cells in the
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innate immune system. PRRs include the well-known transmembrane Toll-like receptors (TLRs), and
an increasing pool of Toll-unrelated receptors (so we call them “Toll-free” receptors hereafter) that
include retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), Caterpiller-like receptors (CLRs),
the HIN200/PYHIN family of nuclear antigens, cGMP-AMP synthase (cGAS), DNA-dependent
activator of IRFs (DAI) [1], DDX9, DDX36 [2], DDX41 [3,4], RNA polymerase III [5], Ku70 [6],
MRE11 [7], Sox2 [8], LRRFIP1 [9], ISG56/IFIT1 [10] and OASs [11], amongst others [12–15].
Intracellular PRRs, including endosomal TLRs, are able to recognize nucleic acids to trigger signal
cascades for the activation of NFκB and specific interferon regulatory factors (IRFs) leading to
production of type I interferons (IFN-I) [15]. Among these “Toll-free” receptors, RLRs and cGAS play
non-redundant roles in the recognition of cytosolic RNAs and DNAs respectively, and they govern
intracellular IFN-I-mediated innate immune responses. The involvement of other cytosolic “Toll-free”
sensing pathways in IFN-I-mediated innate immunity is controversial due to the lack of solid evidence
of genetic studies [16]. Importantly, recent studies have shown that the IFN-I signaling pathway plays
a dual role in chronic viral infections. At the early stage of infection, it has a potent antiviral activity;
however, at late stages, a low level of prolonged IFN-I response facilitates the establishment and
maintenance of persistent infection [17–22].
Except PAMPs, host damage-associated molecular patterns (DAMPs), such as self-nuclei acids,
heat-shock proteins and HMGB1, are also recognized by PRRs [13]. Self-DNA can be accumulated in
the cytoplasm in mammalian cells under stress and specific physiological conditions, including but not
limited to apoptosis, DNA damage, and spontaneous aging/senescence. [14,23,24]. Reactive oxygen
species (ROS) produced from damaged mitochondria are one of the major cause of DNA damage,
especially those with double-strand breaks, apart from other servere effects such as cell-cycle arrest,
senescence and cell death [25–29]. Accumulation of damaged DNA fragments is able to activate
cGAS- or RIG-I-mediated aberrant production of persistent IFN-I and AIM2-mediated inflammatory
responses, causing autoimmune diseases and cancerogenesis [16,30–35]. Persistent IFN-I production
also triggers chronic immune activation, and ultimately results in immune exhaustion and senescence,
in the setting of persistent infection by viruses such as HIV and HCV [19,36,37].
Furthermore, there is substantial evidence showing that prolonged IFN-I signaling has important
roles in regulating T cell responses in both direct and indirect manners, either promoting or inhibiting
T cell activation, proliferation, differentiation and survival, and thus serves as a bridge that links innate
and adaptive immune responses [19,20,21,38,39,40]. For example, CD4+ T cells derived from HIV+
subjects display an anergic phenotype, and a recent report has shown that engagement of TLR7 in
HIV-infected CD4+ T cells induces anergy/unresponsiveness, accounting for the impaired T cell
function by chronic HIV infection [41].
In essence, IFN-I production has to be finely tuned to ensure appropriate mounting of antiviral
and anti-tumor immunity and to maintain cellular homeostasis. We outline the “Toll-free” pathways
triggering IFN-I production in this review, highlighting cGAS, HIN200, and RLRs, and recent updates
on their regulation by cellular and viral factors with enzymatic activities.
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2.

“Toll-free” Nucleic Acid-Sensing Innate Immune Pathways

2.1. cGAS-STING cytosolic dsDNA-sensing pathway
cGMP-AMP synthase (cGAS) synthesizes 2’3’-GMP-AMP (cGAMP) from ATP and GTP after
binding to double-stranded DNA (dsDNA), and is the primary indispensable cytosolic sensor for both
exogenous and endogenous dsDNA molecules, which, with the sizes of as short as 20 bp, are
recognizable by high concentrations of cGAS or, with long sizes with bounded protein, recognizable
by lower concentrations of cGAS [42]. In conjunct with ER-anchored IFN-inducible stimulator of
interferon genes (STING, also called MITA, ERIS, MYPR) that functions as an adaptor to bind to
cGAMP, cGAS-STING-mediated pathway plays a key role in innate immune responses against a large
spectrum of DNA viruses (HSV1, vaccinia virus, adenovirus, KSHV, etc.), retroviruses (HIV1,
HIV2, etc.) that produce pro-integrating DNA molecules, as well as bacteria (Mycobacteria,
Legionella, Listeria, etc.) (Figure 1). In addition to viral infection, chemotherapeutic agents such as
cisplatin, etoposide, and chitosan, induce oxidative DNA damage that promotes self-DNA leakage
from the nucleus and mitochondrion, and therefore trigger cGAS-STING-mediated antitumor immune
response (Figure 1) [28]. dsDNA molecules derived from retrotransposons such as short interspersed
nuclear elements (SINEs) and Alu elements, can also function as ligands for cGAS. Approximately
half of the mammalian genomes consist of retrotransposons [43].

Figure 1. cGAS-STING pathway senses cytosolic dsDNA. Cytosolic dsDNA derived
from invading DNA viruses or retroviruses, or from self-genome under stress
conditions (such as damaged mitochondrial DNA) binds to cGAS, leading the synthesis of
cGAMP from ATP and GTP. cGAMP binds to STING dimers, resulting in STING
phosphorylation and activation, further triggering downstream pathways for production of
IFN-I and proinflammatory cytokines.
AIMS Allergy and Immunology
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Binding of cGAMP to two STING protomers results in translocation of STING from the ER
compartment to perinuclear autophagy-like vesicles, where TBK1 is autophosphorylated and recruited
to STING, allowing STING to be phosphorylated at Ser366, which is in an evolutionary conserved
serine cluster shared with MAVS, TRIF, and IRF3 so that they all are also activated through similar
phosphorylation-dependent mechanism [44]. Phosphorylated STING further recruits IRF3, resulting
in its phosphorylation and activation by TBK1. cGAMP can be transferred to adjacent non-infected
cells to spread antiviral activity, by diffusion or by being packed into viral particles, and therefore
cGAS-STING can mount unique regional immune response [28].
STING itself is a receptor for bacterial cyclic dinucleotides (CDN) and their binding activates
IFN-I responses in mice but not in humans (Figure 1). Binding of CDN to STING dimers causes the
relief of STING autoinhibition, which allows STING to be ubiquitinated with K27 chains by the
ER-anchored E3 ligases AMFR, further leading to the recruitment of TBK1 for IRF3 activation [45].
2.2. HIN200-mediated cytosolic dsDNA-sensing pathways
Except cGAS, two other important receptors for cytosolic dsDNA, AIM2 and IFI16, belong to the
HIN200/PYHIN family that includes 4 members in humans: AIM2 (PYHIN4), IFI16 (PYHIN2),
IFIX (PYHIN1), and MNDA (PYHIN3). The members are hematopoietic interferon-inducible nuclear
antigens with 200 amino acid repeats and an N-terminal PYHIN (Pyrin and HIN) domain (except p202
in mice). Upon binding to DNA, both AIM2 and IFI16 trigger signal transduction to activate caspase 1
inflammasome leading to cleavage of pro-IL1β and pro-IL18 into mature bioactive IL1β and IL18 via
the CARD-containing adaptor ASC (CARD5) [46]. IFI16 preferentially recognizes longer naked
DNA (>150 bp), and also triggers IFN-I responses via STING, in addition to its ability to induce
caspase 1 inflammasome. AIM2 also triggers signal to caspase3-dependent apoptosis (Figure 2). Like
cGAS, IFI16 and AIM2 bind to DNA independent of the DNA sequence [46].
Infection of a DNA virus activates both cGAS and IFI16 in the cytoplasm. However, recent
studies support that DNA viral genome initiates IFI16-mediated immune response in the nucleus,
where episomal genomes of almost all DNA viruses residue and replicate [47]. At the same time, viral
infection (such as herpesviruses) imposes cellular stress that triggers mitochondrial DNA damage and
release to activate cGAS-STING pathway [48]. Of special interest, Epstein-Barr Virus (EBV) latent
infection, which is associated with various malignancies, constitutively induces IFI16-ASC-caspase 1
inflammasome that may represent a chronic inflammatory microenvironment for EBV-mediated
oncogenesis [49].
Single-stranded DNA (ssDNA) derived from retroviral genome reverse transcription or from
DNA replication (named Y-form DNA) potently stimulates IFN-I responses depending on cGAS or
IFI16; whereas the RNA:DNA intermediate derived from reverse transcription prior to host genomic
integration is detected by TLR9 and cGAS [50].
The other two HIN200 family members, IFIX and MNDA, are less studied but existing evidence
has shown that they are involved in regulation of IFN signaling in cancers. IFIX promotes
ubiquitination-mediated degradation of MDM2, leading to p53 stabilization, and stimulates maspin
expression by promoting ubiquitination-mediated degradation of HDAC1, leading to impaired
invasion activity of cancer cells.
AIMS Allergy and Immunology
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Figure 2. HIN200-mediated cytosolic dsDNA-sensing pathways. The dsDNA sensors
AIM2 and IFI16 in the HIN200 family recognize long viral genome DNA in the cytoplasm,
triggering caspase 3-mediated apoptosis and caspase 1-mediated inflammation.
Recognition of dsDNA by IFI16 also triggers STING-mediated IRF3/7 activation and
IFN-I production. While AIM2 activates caspases to trigger apoptosis and inflammation,
mouse P202 inhibits AIM2-mediated pathways.
2.3. RLR cytosolic RNA-sensing pathways
RLRs include RIG-I (DDX58), MDA5 (IFIH1), and LGP2, all of which contain a central DEAD
box helicase/ATPase domain and a C-terminal regulatory domain (CTD); the latter (CTD) is essential
for RNA binding. RIG-I and MDA5 each contains 2 CARD domains, and both signal through the
mitochondrial CARD-containing antiviral signaling adaptor MAVS (also called VISA, IPS1, or
CARDIF) that is located on mitochondrial membrane. RIG-I recognizes dsRNA synthesized from
AT-rich dsDNA derived from DNA viruses (EBV, HSV1) and bacteria [5], and recognizes 5’-ppp
ssRNA derived from the RNA viruses NDV, VSV, Sendai virus, influenza A virus and JEV; while
MDA5 recognizes >300 bp long dsRNA such as poly (I:C) and RNA from EMCV and
paramyxovirus (Figure 3) [51]. Solid evidence have shown that STING is also involved in RIG-I
signaling, and interacts with MAVS in a complex that is stabilized in response to RNA virus infection,
potentiating RIG-I-mediated antiviral responses (Figure 3) [51]. In the absence of ligand challenges,
RIG-I and MDA5 are inactive due to phosphorylation at specific Thr and Ser residues (Ser8 and
Thr170 of RIG-I, and Ser88 of MDA5), which is mediated by casein kinase II (CKII) and protein
kinase C (PKC)-α/β respectively for RIG-I and by RIOK3 for MDA5. Activation of RIG-I and MDA5
requires their dephosphorylation by PP1α/γ, ubiquitination, and ATP-dependent conformational
changes leading to their multimerization upon binding to RNA. The other member, LGP2, can
recognize RNA but lacks CARD domains, and results from knockout mice have shown that LGP2 is in
AIMS Allergy and Immunology
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fact a positive regulator of RIG-I/MDA5 signaling [52]. Different from TLRs that are restrictedly
expressed in immune cells, epithelial cells and synovial fibroblasts, RLRs are expressed in most cell
types.

Figure 3. RLR-mediated RNA sensing pathways. RIG-I and MDA5 recognize different
patterns of cytosolic RNA fragments derived from viruses, bacteria, or the host cell.
STING interacts with RIG-I and MAVS in a complex that is stabilized upon RNA virus
infection, facilitating the antiviral response. In addition, AT-rich dsDNA derived from
bacteria or DNA viruses can be transcribed by RNA polymerase III into 5’-ppp dsRNA,
which activates RIG-I-MAVS-TBK1-IRF3 pathway for IFN-I production.
2.4. Other “Toll-free” cytosolic innate sensing pathways for IFN-I production
An increasing pool of individual cytosolic DNA and RNA sensors have been identified. Almost
all these sensors trigger IFN-I production [13], except OASs that recognize dsRNA leading to RNA
degradation by RNase L, and Sox2 that recognizes dsDNA triggering NFκB/AP1-mediated
inflammation via activating the kinase complex TAK1-TAB2 (Figure 4) [8]. The adaptor STING
converges different DNA sensing pathways for IRF3 activation leading to IFN-I production [53].
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Figure 4. Cytosolic nucleic acid sensors triggering innate immune responses. An
increasing pool of cytosolic “Toll-free” nucleic acid sensors have been identified in
addition to cGAS-STING, RLRs, and the HIN200 family. They usually use STING to
transmit their signal for the production of IFN-I via activating IRF3.
3.

Evasion of “Toll-free” Innate Signaling Pathways

Innate sensing pathways are circumvented by numerous viral and cellular negative
regulators (Figures 5 and 6). For example, Kaposi’s sarcoma-associated herpesvirus (KSHV)-encoded
ORF52 and its homologs in other gammaherpesviruses (EBV, MHV68 and Rhesus monkey
Rhadinovirus) inhibit cGAS activity to facilitate virus progeny [54,55]; KSHV-encoded vIRF1
negatively regulates STING-TBK1 interaction [56], and vIRF4 inhibits IRF7 transcriptional
activity [57]. Some dsDNA and ssDNA viruses express proteins, including HPV E7 and human
adenovirus E1A oncoproteins, with the Leu-x-Cys-x-Glu (LxCxE) motif that is known to block the Rb
tumor suppressor [58]. The LxCxE motif mediates their interaction with STING to block IFN-I
immune responses. Since these proteins are frequently used to immortalize cell lines [59],
cGAS-STING pathway in these immortalized cell lines is compromised [50].
Nevertheless, those regulators with enzyme activities, such as DNA and RNA editing enzymes,
kinases and phosphatases, ubiquitin E3 ligases and deubiquitinases, and histone modification enzymes,
are especially interesting in that these regulators are potentially targeted with enzyme inhibitors for
clinical interventions. In regard to evasion of HIV infection, these interesting enzymes include the
RNA editing enzyme APOBEC3G, the ubiquitin E3 ligases TRIM5α and TRIM22, the exonucleases
TREX1 and SAMHD1, and the GTPase Mx2, and they are all inducible by IFN-I. Tetherin (BST2),
another IFN-inducible host restriction factor with broad antiviral activity (including HIV1), directly
tethers virions for internalization, leading to endocytosis and subsequently degradation [60,61].
Apoptotic caspases have also been found to negatively regulate cGAS-STING pathway, although the
AIMS Allergy and Immunology
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precise mechanism remains unclear [24,62]. Of note, many PRRs themselves have enzymatic activity,
including RLRs, cGAS, and DDXs, and some of their family members negatively regulate PRR
signaling pathways; for example, DDX46 negatively regulates IFN-I responses by retaining antiviral
mRNAs of TRAF3, TRAF6, and MAVS in the nucleus through eliminating their m6A modification [63].

Figure 5. Regulation of cGAS and STING by cellular and viral factors. Phosphorylation
and ubiquitination are two major posttranslational modifications that regulate cGAS and
STING protein stability and activity. Many viral factors, with or without enzyme activity,
may also regulate their activities through other mechanisms, including direct interaction
and employment of cellular factors as mediators.
Apart from protein regulators, miRNAs represent another interesting category of immune
inhibitors with clinical potentials [64,65,66]. For example, miR-27 targets STING gene 3’UTR and
represses its expression, resulting in impaired CCL22-mediated recruitment of Tregs in human
papillomavirus (HPV)-positive tongue squamous cell carcinoma (TSCC) [67]. STING, in addition to
MAVS and IRF3, is also targeted for downregulation by miR-576-3p [68]. Hypoxia induces
Tet1-dependent expression of miR-25/93 that targets NCOA3, a lysine acetyltransferase that
epigenetically induces cGAS expression in cooperation with AP1, resulting in suppression of cGAS
expression in hypoxic breast cancers [69].
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Figure 6. Regulation of RLR signaling components. The receptors RIG-I and MDA5, the
adaptor MAVS, and the downstream IRF3/7 are shown as examples in the RLR signaling
pathways for their regulation by phosphorylation and ubiquitination at the
posttranslational level. Many viral factors may also regulate their activities through other
mechanisms.
3.1. Evasion of nucleic acid sensing pathways by AGS exonucleases
The family of AGS exonucleases, including AGS1-5, are RNases except AGS1 (TREX1) that
functions as a DNase. However, our recent in vitro biochemical evidence have shown that AGS1 can in
fact also act as an RNase, which specifically degrades ssRNA [70]. Attraction is especially focused on
AGS1 and AGS5 (SAMHD1) because of their roles in HIV1 infection. TREX1 is responsible for the
degradation of self-DNA in the cytosol. In the absence of TREX1, viral infections including HIV1
infection cause accumulation of cytoplasmic DNA, which activates the cGAS-STING pathway
leading to IFN-I production and eventually viral replication is inhibited. Deficiency of TREX1 also
causes Aicardi-Goutieres syndrome, a childhood inflammatory disorder characterized by high
endogenous levels of IFN-I resulting from activation of DNA sensors by excess endogenous DNA.
3.2. Evasion of RNA sensing pathways by RNA editing enzymes
The RNA editing enzymes in humans consist of the adenosine deaminases that act on
RNA (ADARs, A-to-I) family and the cytidine deaminases (AID/APOBECs, C-to-U) family.
The double-stranded RNA (dsRNA) A-to-I adenosine deaminase acting on RNAs (ADARs)
AIMS Allergy and Immunology
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include ADAR1 (IFI4), ADAR2, and ADAR3. ADAR1 has two forms; the longer form p150 is
IFN-inducible but the shorter form p110 is constitutively expressed, ADAR2 is constitutively
expressed, and ADAR3 has no enzyme activity [71]. Bioinformatics analysis has indicated that only
limited sites in human transcriptome are potentially edited by ADARs; however, it is estimated
approximately 20% of the human miRNA precursors are subject to ADAR editing, and in
IFN-mediated antiviral responses, specific editable sites are increased [71]. Also, retrotransposons,
which represent nearly half of the mammalian genomes, undergo extensive A-to-I editing [72].
ADAR1 also competes with RIG-I and MDA5 for dsRNA binding independently of its RNA editing
activity and therefore suppresses IFN response upon RNA virus infection [73], and also negatively
regulates OAS1- and PKR-mediated immune responses. Due to its ability to act on both cellular and
viral dsRNAs, ADAR1 has broad roles in repressing antiviral immunity and preventing autoimmune
diseases [74]. However, for some other viruses, including HCV and influenza virus, A-to-I editing of
viral RNAs promotes antiviral activity [74].
Furthermore, ADARs have been shown to regulate DNA virus latent infection such as the
oncogenic KSHV and EBV that encode ADAR-targeted RNA transcripts [74]. Site-specific A-to-I
RNA editing of KSHV oncogenic K15 transcript (encodes miR-K10 and kaposin A) abrogates its
transforming activity and promotes KSHV replication [75]. The EBV pre-miR-BART6 transcript
undergo A-to-I editing that negatively regulates miR-BART6 biological functions [76]. A-to-I editing
of viral transcripts at multiple sites may alter ORFs and results in aberrant expression of viral proteins.
The AID/APOBEC C-to-U family, including eleven members, can selectively act on either RNA
or ssDNA [77]. Among these members, AID and APOBEC3 (APOBEC3A-H), are of great interest
due to their antiviral activity against HBV, HCV, HIV, HTLV1, HPV, and herpesvirus infection [77].
The ssDNA deaminase AID, which is primarily expressed in germinal center (GC) B cells and is the
only enzyme known to induce oncogenic mutations in the human genome, is induced upon infection
with HCV or Helicobacter pylori, and is also induced by EBV LMP1 and HTLV1 Tax via NFκB in
their latency. APOBEC3 deaminases are only expressed in mammalians and inhibit retroviral infection
by deaminating their DNA intermediates. For example, APOBEC3G defends viral infectivity
factor 1 (VIF1)-deficient HIV infection; however, VIF1 causes APOBEC3G ubiquitination-dependent
degradation. Similar to AID, APOBEC editing causes endogenous “off-target” DNA damage and
genomic instability favoring cancer development, for example, in the setting of oncogenic HPV
infection [77].
3.3. Evasion of type I IFN responses by protein kinases and phosphatases
Protein kinases usually activate PRR signaling by phosphorylating their components on specific
sites. For example, the adaptors TRIF, MAVS and STING are phosphorylated at a serine site in a
conserved motif pLxIS by TBK1 and IKKε for the recruitment of IRF3 [44], and phosphorylation of
IRF3 and IRF7 by IKKs or IRAK1 is prerequisite for their activation leading to IFN-I production.
STING Ser366 phosphorylation by TBK1 is believed to be required for its activation [44], although
another report showed that phosphorylation of this site by autophagy-related kinases ULK1 (ATG1)
and ULK2 diminishes STING activity [78]. However, site-specific phosphorylation of some
components may cause their inactivation. For example, phosphorylation of human cGAS S305 (S291
AIMS Allergy and Immunology
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in mouse) by Akt potently inhibits cGAS enzymatic activity [79]. Phosphorylation of IRF3 Ser97
inhibits its activity but the phosphatase pTEN releases this inhibition to promote IRF3-mediated IFN-I
antiviral responses [80]. Phosphorylation of RIG-I by IKKε or PKCα/β negatively regulates its
activity.
Recently, the roles of protein phosphatases in antiviral immune responses have emerged. PP1 and
PP2A are positive regulators of Tat-dependent HIV1 transcription, and the 35QVCF38 motif of Tat
directly interacts with PP1 [81]. PP1 also dephosphorylates the RNA sensors, MDA5 and RIG-I, and
positively regulates their activity for IFN-I production in response to RNA virus infection [82,83].
Additionally, PP1 interacts with TRAF6, and promotes TRAF6-dependent innate immune responses [84].
In contrast, PP1 dephosphorylates Ebola virus VP30 and inhibits its transcription [85]. The
measles virus V and the HBV X proteins can antagonize PP1 activity to facilitate their
replication [83,86]. PP1 negatively regulates IRF3-mediated IFN-I production by inhibiting its
phosphorylation at serines 396 and 385 [87], and together with GADD34, negatively regulates
TLR-mediated immune response by inhibiting TAK1 serine 412 phosphorylation [88,89]. PP2A also
deactivates IRF3 in cooperation with FBXO17 [90], and inhibits IFN-I signaling by inhibiting STAT1
phosphorylation and therefore contributes to HCV chronic infection [91]. More recently, we have
identified PP1 as the first phosphatase that inactivates IRF7 by targeting its key phosphorylation sites
and abrogates IRF7-mediated IFN-I responses [92]. Further verification of this important finding in
mouse models in vivo is necessary.
3.4. Evasion of “Toll-free” innate pathways by ubiquitinases and deubiquitinases
Besides phosphorylation/dephosphorylation, ubiquitination/deubiquitination represent another
major epigenetic modification that is committed to fine regulation of myriad cellular functions. It
seems all components in each PRR signaling pathway, including the receptor, the adaptor, TRAFs, and
downstream IRFs, are regulated by ubiquitination (Figures 5 and 6) [93,94,95]. The involved cellular
E3 ligases mainly include the TRAF, TRIM, and RNF families, and the cellular deubiquitinases mainly
include the OTU and USP families [96,97]. For example, the deubiquitinases Gumby (OTULIN),
OTUD7b, and TNFAIP3 (A20) in the OUT family were shown to negatively regulate NFκB activation
through different mechanisms in different biological contexts [98–104].
The ER-anchored RNF185 triggers K27-linked ubiquitination of cGAS promoting its
activation [105]; AMFR-mediated K27-linked ubiquitination and TRIM32, TRM56, or
MUL1-mediated K63-linked ubiquitination of STING are required for its activation [45,106,107,108],
but HTLV1 Tax and HBV polymerase negatively regulate STING K63-linked ubiquitination, and the
cellular E3 ligases RNF5 and TRIM30α triggers STING K48-linked ubiquitination and degradation to
alleviate cytosolic DNA sensing pathways [109–112]. RNF26 protects STING from RNF5-mediated
degradation by targeting the same site (K150) for K11-linked ubiquitination, whereas promotes
autophagy-mediated degradation of IRF3 [113]. USP21, a deubiquitinase, is recruited to STING after
HSV1-stimulated phosphorylation via p38 and negatively regulates STING activity by hydrolyzing
K27- and K63-linked ubiquitin chains of STING [114].
TRIM65 triggers K63-linked ubiquitination of MDA5 [115], and TRIM31 triggers K63-linked
ubiquitination of downstream adaptor MAVS [116], both promoting RIG-I signaling pathway;
AIMS Allergy and Immunology
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whereas the membrane-anchored TRIM13 and TRIM59 negatively regulate MDA5-mediated IFN-I
responses but promotes RIG-I activity through unclear mechanism that may involve additional
cofactors [117]. TRIM4, TRIM25/RNF147, and Reul/RNF135/RIPLET E3 ligases promotes RIG-I
K63-linked ubiquitination and activation [118–122]. In contrast, RNF122 and RNF125 target RIG-I
for ubiquitination-mediated degradation [123,124].
TRIM21 targets IRF3 and DDX41, and TRIM26 and SENP2 target IRF3, for degradation, and
TRIM21 also negatively regulates FADD-mediated antiviral immunity. TRIM35 targets IRF7 for
degradation. We have shown that TRAF6 E3 ligase promotes IRF7 K63-linked ubiquitination that is
required for EBV LMP1 activation of IRF7 [125]; however, A20, a member with both E3 ligase and
deubiquitinase activities in the OTU family, inhibits LMP1-stimulated IRF7 activity by acting as a
deubiquitinase [126].
In recent years, LUBAC-mediated linear polyubiquitination is coming into focus due to its
emerging role in activation of NFκB in response to diverse signaling stimuli [127–132], including
apoptotic and immune stimuli such as TNFα [133,134], IL1β [135], genotoxic stress [136], CD40 [137],
Toll-like receptors (TLRs) [138], NOD2 [98], and NLRP3 [139]. LUBAC is a ternary ubiquitin ligase
complex composed of HOIP (RNF31), HOIL1L (RNF54), and SHARPIN, and is constitutively
formed under normal physiological conditions [133,134,140]. RNF31 is likely the central component
of this complex [141]. LUBAC components are abundantly expressed in thymus and spleen, implying
its potential role in lymphocytes [130]. Recent reports clearly show that LUBAC specifically activates
the canonical NFκB pathway, but not the JNK pathway, by conjugating linear polyubiquitin chains
onto NEMO and RIP1 [130,142] . However, LUBAC negatively regulates RIG-I-mediated innate
immune responses by targeting RIG-I, TRIM25 and IRF3 for degradation [143,144], and by disrupting
the TRAF3-MAVS complex [145]. We have recently shown that LUBAC-mediated linear
ubiquitination is required for LMP1 activation of NFκB, but inhibits LMP1-stimulated IRF7
activity [146].
Compared with host cellular factors, virus-encoded factors are of greater interest in that they are
virus-specific and easier to manipulate without affecting bypass cellular functions. Herpesvirus-encoded
E3 ligases have been found to play crucial roles in evading innate immune responses for facilitating their
infection and establishment of latent infection. For example, HSV1 ICP0 and HCMV pUL83 ubiquitin
E3 ligases target IFI16 for proteasome-dependent degradation [147,148]. KSHV IE lytic transactivator
RTA/ORF50 functions as a ubiquitin E3 ligase that targets IRF7 for degradation [149]. Herpesviruses
also encode deubiquitinases, many of which have also been shown to evade innate immune responses.
For example, EBV-encoded BPLF1 functions as a deubiquitinase that suppresses NFκB activation
downstream of TLR signaling [150].
Ubiquitination-like modifications, especially sumoylation, have been shown to exert similar
functions to ubiquitination in antiviral regulation. For example, TRIM38 stabilizes cGAS and STING
by promoting their sumoylation [151], and TRIM28 is a SUMO E3 ligase that promotes IRF7
sumoylation and negatively regulates its activity [152]. These intriguing findings have advanced our
current understanding of the novel functions of ubiquitination-like posttranslational modifications in
signal transduction pathways [153,154].
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4.

Closing Remarks

The increasing pool of cytosolic nucleic acid receptors have greatly advanced the study of
IFN-I-mediated innate immune mechanisms, and may also shed light on type III IFNs-mediated
responses that involve similar induction mechanisms to IFN-I. It is plausible that better understanding
of innate immune pathways will benefit clinical applications for both antiviral infections and
inflammation-related diseases including cancers. Recent research brings cGAS-STING pathway to the
focus for potential treatments of cancers in that this pathway plays crucial roles in antitumor immunity
and is aberrantly regulated in many cancers [28]. Future efforts may concentrate on the identification
of viral and cellular regulators of these signaling pathways so as to design appropriate strategies such
as cancer vaccines to evoke or interfere with their functions in different related disease settings,
including cancers and autoimmune disorders.
Acknowledgements
This work was supported by an NIH grant to SN (1R15DE027314) and in part by the NIH grant
C06RR0306551. This publication is the result of work supported with resources and the use of
facilities at the James H. Quillen Veterans Affairs Medical Center. The contents in this publication do
not represent the views of the Department of Veterans Affairs or the United States Government.
Conflict of Interest
The authors declare that they have no competing interests in this paper.
References
1.
2.

3.

4.
5.
6.

Takaoka A, Wang Z, Choi MK, et al. (2007) DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and
an activator of innate immune response. Nature 448: 501–505.
Kim T, Pazhoor S, Bao M, et al. (2010) Aspartate-glutamate-alanine-histidine box motif
(DEAH)/RNA helicase A helicases sense microbial DNA in human plasmacytoid dendritic cells.
Proc Natl Acad Sci USA 107: 15181–15186.
Parvatiyar K, Zhang Z, Teles RM, et al. (2012) The helicase DDX41 recognizes the bacterial
secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune
response. Nat Immunol 13: 1155–1161.
Zhang Z, Yuan B, Bao M, et al. (2011) The helicase DDX41 senses intracellular DNA mediated
by the adaptor STING in dendritic cells. Nat Immunol 12: 959–965.
Chiu YH, MacMillan JB, Chen ZJ (2009) RNA polymerase III detects cytosolic DNA and induces
type I interferons through the RIG-I pathway. Cell 138: 576–591.
Zhang X, Brann TW, Zhou M, et al. (2011) Ku70 is a novel cytosolic DNA sensor that induces
type-III rather than type-I IFN. J Immunol 186: 4541–4545.

AIMS Allergy and Immunology

Volume 1, Issue 3, 143-163.

156

7.

8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.

21.
22.
23.

24.
25.
26.

Kondo T, Kobayashi J, Saitoh T, et al. (2013) DNA damage sensor MRE11 recognizes cytosolic
double-stranded DNA and induces type I interferon by regulating STING trafficking. Proc Natl
Acad Sci USA 110: 2969–2974.
Xia P, Wang S, Ye B, et al. (2015) Sox2 functions as a sequence-specific DNA sensor in
neutrophils to initiate innate immunity against microbial infection. Nat Immunol 16: 366–375.
Yang P, An H, Liu X, et al. (2010) The cytosolic nucleic acid sensor LRRFIP1 mediates the
production of type I interferon via a beta-catenin-dependent pathway. Nat Immunol 11: 487–494.
Pichlmair A, Lassnig C, Eberle CA, et al. (2011) IFIT1 is an antiviral protein that recognizes
5’-triphosphate RNA. Nat Immunol 12: 624–630.
Hornung V, Hartmann R, Ablasser A, et al. (2014) OAS proteins and cGAS: unifying concepts in
sensing and responding to cytosolic nucleic acids. Nat Rev Immunol 14: 521–528.
Ori D, Murase M, Kawai T (2017) Cytosolic nucleic acid sensors and innate immune regulation.
Int Rev Immunol 36: 74–88.
Xia P, Wang S, Gao P, et al. (2016) DNA sensor cGAS-mediated immune recognition. Protein
Cell 7: 777–791.
Schlee M, Hartmann G (2016) Discriminating self from non-self in nucleic acid sensing. Nat Rev
Immunol 16: 566–580.
Ning S, Pagano J, Barber G (2011) IRF7: activation, regulation, modification, and function.
Genes Immun 12: 399–414.
Chen Q, Sun L, Chen ZJ (2016) Regulation and function of the cGAS-STING pathway of
cytosolic DNA sensing. Nat Immunol 17: 1142–1149.
Wilson EB, Yamada DH, Elsaesser H, et al. (2013) Blockade of chronic type I interferon signaling
to control persistent LCMV infection. Science 340: 202–207.
Teijaro JR, Ng C, Lee AM, et al. (2013) Persistent LCMV infection is controlled by blockade of
type I interferon signaling. Science 340: 207–211.
Cha L, Berry CM, Nolan D, et al. (2014) Interferon-alpha, immune activation and immune
dysfunction in treated HIV infection. Clin Trans Immunol 3: e10.
Catalfamo M, Wilhelm C, Tcheung L, et al. (2011) CD4 and CD8 T cell immune activation during
chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7. J Immunol 186:
2106–2116.
Crouse J, Kalinke U, Oxenius A (2015) Regulation of antiviral T cell responses by type I
interferons. Nat Rev Immunol 15: 231–242.
Bosque A, Planelles V (2009) Induction of HIV-1 latency and reactivation in primary memory
CD4+ T cells. Blood 113: 58–65.
Härtlova A, Erttmann SF, Raffi FAM, et al. (2015) DNA damage primes the type i interferon
system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity.
Immunity 42: 332–343.
White MJ, McArthur K, Metcalf D, et al. (2014) Apoptotic caspases suppress mtDNA-induced
STING-mediated type I IFN production. Cell 159: 1549–1562.
Vilenchik MM, Knudson AG (2003) Endogenous DNA double-strand breaks: production, fidelity
of repair, and induction of cancer. Proc Natl Acad Sci USA 100: 12871–12876.
de Galarreta MR, Lujambio A (2017) DNA sensing in senescence. Nat Cell Biol 19: 1008–1009.

AIMS Allergy and Immunology

Volume 1, Issue 3, 143-163.

157

27. Gluck S, Guey B, Gulen MF, et al. (2017) Innate immune sensing of cytosolic chromatin
fragments through cGAS promotes senescence. Nat Cell Biol 19: In press.
28. Ng KW, Marshall EA, Bell JC, et al. (2017) cGAS-STING and cancer: dichotomous roles in
tumor immunity and development. Trends Immunol: In press.
29. Yang H, Wang H, Ren J, et al. (2017) cGAS is essential for cellular senescence. Proc Natl Acad
Sci USA 114: E4612–E4620.
30. Baccala R, Hoebe K, Kono DH, et al. (2007) TLR-dependent and TLR-independent pathways of
type I interferon induction in systemic autoimmunity. Nat Med 13: 543–551.
31. Shibutani ST, Saitoh T, Nowag H, et al. (2015) Autophagy and autophagy-related proteins in the
immune system. Nat Immunol 16: 1014–1024.
32. Agod Z, Fekete T, Budai MM, et al. (2017) Regulation of type I interferon responses by
mitochondria-derived reactive oxygen species in plasmacytoid dendritic cells. Redox Biol 13:
633–645.
33. McNab F, Mayer-Barber K, Sher A, et al. (2015) Type I interferons in infectious disease. Nat Rev
Immunol 15: 87–103.
34. Forster S (2012) Interferon signatures in immune disorders and disease. Immunol Cell Biol 90:
520–527.
35. Elkon KB, Wiedeman A (2012) Type I IFN system in the development and manifestations of SLE.
Curr Opin Rheumatol 24: 499–505.
36. Sandler NG, Bosinger SE, Estes JD, et al. (2014) Type I interferon responses in rhesus macaques
prevent SIV infection and slow disease progression. Nature 511: 601–605.
37. Mogensen T, Melchjorsen J, Larsen C, et al. (2010) Innate immune recognition and activation
during HIV infection. Retrovirology 7: 54.
38. Tough DF (2012) Modulation of T-cell function by type I interferon. Immunol Cell Biol 90:
492–497.
39. Zitvogel L, Galluzzi L, Kepp O, et al. (2015) Type I interferons in anticancer immunity. Nat Rev
Immunol 15: 405–414.
40. Gajewski TF, Corrales L (2015) New perspectives on type I IFNs in cancer. Cytokine Growth F R
26: 175–178.
41. Dominguez-Villar M, Gautron AS, de Marcken M, et al. (2015) TLR7 induces anergy in human
CD4+ T cells. Nat Immunol 16: 118–128.
42. Andreeva L, Hiller B, Kostrewa D, et al. (2017) cGAS senses long and HMGB/TFAM-bound
U-turn DNA by forming protein-DNA ladders. Nature: In press.
43. Cordaux R, Batzer MA (2009) The impact of retrotransposons on human genome evolution. Nat
Rev Genet 10: 691–703.
44. Liu S, Cai X, Wu J, et al. (2015) Phosphorylation of innate immune adaptor proteins MAVS,
STING, and TRIF induces IRF3 activation. Science 347.
45. Wang Q, Liu X, Cui Y, et al. (2014) The E3 ubiquitin ligase AMFR and INSIG1 bridge the
activation of TBK1 kinase by modifying the adaptor STING. Immunity 41: 919–933.
46. Man SM, Karki R, Kanneganti TD (2016) AIM2 inflammasome in infection, cancer, and
autoimmunity: role in DNA sensing, inflammation, and innate immunity. Eur J Immunol 46:
269–280.
AIMS Allergy and Immunology

Volume 1, Issue 3, 143-163.

158

47. Diner BA, Lum KK, Cristea IM (2015) The emerging role of nuclear viral DNA sensors. J Biol
Chem 290: 26412–26421.
48. West AP, Khoury-Hanold W, Staron M, et al. (2015) Mitochondrial DNA stress primes the
antiviral innate immune response. Nature 520: 553–557.
49. Ansari MA, Singh VV, Dutta S, et al. (2013) Constitutive interferon-inducible protein
16-inflammasome activation during Epstein-Barr virus latency I, II, and III in B and epithelial
cells. J Virol 87: 8606–8623.
50. Christensen MH, Paludan SR (2017) Viral evasion of DNA-stimulated innate immune responses.
Cell Mol Immunol 14: 4–13.
51. Zevini A, Olagnier D, Hiscott J (2017) Crosstalk between cytoplasmic RIG-I and STING sensing
pathways. Trends Immunol 38: 194–205.
52. Satoh T, Kato H, Kumagai Y, et al. (2010) LGP2 is a positive regulator of RIG-I- and
MDA5-mediated antiviral responses. Proc Natl Acad Sci USA 107: 1512–1517.
53. Kato K, Omura H, Ishitani R, et al. (2017) Cyclic GMP-AMP as an endogenous second
messenger in innate immune signaling by cytosolic DNA. Annu Rev Biochem 86: 541–566.
54. Wu JJ, Li W, Shao Y, et al. (2015) Inhibition of cGAS DNA sensing by a herpesvirus virion
protein. Cell Host Microbe 18: 333–344.
55. Li W, Avey D, Fu B, et al. (2016) Kaposi’s sarcoma-associated herpesvirus inhibitor of
cGAS (KicGAS), encoded by orf52, is an abundant tegument protein and is required for
production of infectious progeny viruses. J Virol 90: 5329–5342.
56. Ma Z, Jacobs SR, West JA, et al. (2015) Modulation of the cGAS-STING DNA sensing pathway
by gammaherpesviruses. Proc Natl Acad Sci USA 112: E4306–E4315.
57. Hwang SW, Kim D, Jung JU, et al. (2017) KSHV-encoded viral interferon regulatory
factor 4 (vIRF4) interacts with IRF7 and inhibits interferon alpha production. Biochem Bioph Res
Co 486: 700–705.
58. Lau L, Gray EE, Brunette RL, et al. (2015) DNA tumor virus oncogenes antagonize the
cGAS-STING DNA-sensing pathway. Science 350: 568–571.
59. de Souza RF, Iyer LM, Aravind L (2010) Diversity and evolution of chromatin proteins encoded
by DNA viruses. BBA-Gene Regul Mech 1799: 302–318.
60. Towers GJ, Noursadeghi M (2014) Interactions between HIV-1 and the cell-autonomous innate
immune system. Cell Host Microbe 16: 10–18.
61. Sandstrom TS, Ranganath N, Angel JB (2017) Impairment of the type I interferon response by
HIV-1: potential targets for HIV eradication. Cytokine Growth F R: In press.
62. Rongvaux A, Jackson R, Harman CCD, et al. (2014) Apoptotic caspases prevent the induction of
type I interferons by mitochondrial DNA. Cell 159: 1563–1577.
63. Zheng Q, Hou J, Zhou Y, et al. (2017) The RNA helicase DDX46 inhibits innate immunity by
entrapping m6A-demethylated antiviral transcripts in the nucleus. Nat Immunol 18: 1094–1103.
64. Boss IW, Renne R (2011) Viral miRNAs and immune evasion. BBA-Gene Regul Mech 1809:
708–714.
65. Cullen BR (2013) MicroRNAs as mediators of viral evasion of the immune system. Nat Immunol
14: 205–210.

AIMS Allergy and Immunology

Volume 1, Issue 3, 143-163.

159

66. Wang L, Li G, Yao ZQ, et al. (2015) MicroRNA regulation of viral immunity, latency, and
carcinogenesis of selected tumor viruses and HIV. Rev Med Virol 25: 320–341.
67. Ding L, Huang XF, Dong GJ, et al. (2015) Activated STING enhances Tregs infiltration in the
HPV-related carcinogenesis of tongue squamous cells via the c-jun/CCL22 signal. BBA-Mol
Basis Dis 1852: 2494–2503.
68. Yarbrough ML, Zhang K, Sakthivel R, et al. (2014) Primate-specific miR-576-3p sets host
defense signaling threshold. Nat Commun 5: 4963–4963.
69. Wu MZ, Cheng WC, Chen SF, et al. (2017) miR-25/93 mediates hypoxia-induced
immunosuppression by repressing cGAS. Nat Cell Biol 19: 1286–1296.
70. Yuan F, Dutta T, Wang L, et al. (2015) Human DNA exonuclease TREX1 is also an
exoribonuclease that acts on single-stranded RNA. J Biol Chem 290: 13344–13353.
71. Samuel CE (2011) Adenosine deaminases acting on RNA (ADARs) are both antiviral and
proviral dependent upon the virus. Virology 411: 180–193.
72. Liddicoat BJ, Piskol R, Chalk AM, et al. (2015) RNA editing by ADAR1 prevents MDA5 sensing
of endogenous dsRNA as nonself. Science 349: 1115–1120.
73. Yang S, Deng P, Zhu Z, et al. (2014) ADAR1 Limits RIG-I RNA detection and suppresses IFN
production responding to viral and endogenous RNAs. J Immunol 193: 3436–3445.
74. Wang Q, Li X, Qi R, et al. (2017) RNA Editing, ADAR1, and the innate immune response. Genes
8: 41.
75. Gandy SZ, Linnstaedt SD, Muralidhar S, et al. (2007) RNA editing of the human herpesvirus 8
kaposin transcript eliminates its transforming activity and is induced during lytic replication. J
Virol 81: 13544–13551.
76. Iizasa H, Wulff BE, Alla NR, et al. (2010) Editing of Epstein-Barr virus-encoded BART6
microRNAs controls their dicer targeting and consequently affects viral latency. J Biol Chem 285:
33358–33370.
77. Rebhandl S, Huemer M, Greil R, et al. (2015) AID/APOBEC deaminases and cancer.
Oncoscience 2: 320–333.
78. Konno H, Konno K, Barber GN (2013) Cyclic dinucleotides trigger ULK1 (ATG1)
phosphorylation of STING to prevent sustained innate immune signaling. Cell 155: 688–698.
79. Seo GJ, Yang A, Tan B, et al. (2015) Akt kinase-mediated checkpoint of cGAS DNA sensing
pathway. Cell Rep 13: 440–449.
80. Li S, Zhu M, Pan R, et al. (2016) The tumor suppressor PTEN has a critical role in antiviral innate
immunity. Nat Immunol 17: 241–249.
81. Nekhai S, Jerebtsova M, Jackson A, et al. (2007) Regulation of HIV-1 transcription by protein
phosphatase 1. Curr Hiv Res 5: 3–9.
82. Wies E, Wang MK, Maharaj NP, et al. (2013) Dephosphorylation of the RNA sensors RIG-I and
MDA5 by the phosphatase PP1 is essential for innate immune signaling. Immunity 38: 437–449.
83. Davis ME, Wang MK, Rennick LJ, et al. (2014) Antagonism of the phosphatase PP1 by the
measles virus V protein is required for innate immune escape of MDA5. Cell Host Microbe 16:
19–30.
84. Opaluch AM, Schneider M, Chiang CY, et al. (2014) Positive regulation of TRAF6-dependent
innate immune responses by protein phosphatase PP1-gamma. Plos One 9: e89284.
AIMS Allergy and Immunology

Volume 1, Issue 3, 143-163.

160

85. Ilinykh PA, Tigabu B, Ivanov A, et al. (2014) Role of protein phosphatase 1 in dephosphorylation
of Ebola virus VP30 protein and its targeting for the inhibition of viral transcription. J Biol Chem
289: 22723–22738.
86. Cougot D, Allemand E, Rivière L, et al. (2012) Inhibition of PP1 phosphatase activity by HBx: a
mechanism for the activation of hepatitis B virus transcription. Sci Signal 5: ra1.
87. Gu M, Zhang T, Lin W, et al. (2014) Protein phosphatase PP1 negatively regulates the Toll-like
receptor- and RIG-I-like receptor-triggered production of type I interferon by inhibiting IRF3
phosphorylation at serines 396 and 385 in macrophage. Sci Signal: In press.
88. Gu M, Ouyang C, Lin W, et al. (2014) Phosphatase holoenzyme PP1/GADD34 negatively
regulates TLR response by inhibiting TAK1 serine 412 phosphorylation. J Immunol 192:
2846–2856.
89. Clavarino G, Claudio N, Dalet A, et al. (2012) Protein phosphatase 1 subunit Ppp1r15a/GADD34
regulates cytokine production in polyinosinic: polycytidylic acid-stimulated dendritic cells. Proc
Natl Acad Sci USA: In press.
90. Peng D, Wang Z, Huang A, et al. (2017) A novel function of F-Box protein FBXO17 in negative
regulation of type I IFN signaling by recruiting PP2A for IFN regulatory factor 3 deactivation. J
Immunol 198: 808–819.
91. Shanker V, Trincucci G, Heim HM, et al. (2013) Protein phosphatase 2A impairs IFNα-induced
antiviral activity against the hepatitis C virus through the inhibition of STAT1 tyrosine
phosphorylation. J Viral Hepatitis 20: 612–621.
92. Wang L, Zhao J, Ren J, et al. (2016) Protein phosphatase 1 abrogates IRF7-mediated type I IFN
response in antiviral immunity. Eur J Immunol 46: 2409–2419.
93. Davis ME, Gack MU (2015) Ubiquitination in the antiviral immune response. Virology 479–480:
52–65.
94. Lin D, Zhong B (2015) Regulation of cellular innate antiviral signaling by ubiquitin modification.
Acta Biochim Biophys Sin (Shanghai) 47: 149–155.
95. Heaton SM, Borg NA, Dixit VM (2016) Ubiquitin in the activation and attenuation of innate
antiviral immunity. J Exp Med 213: 1–13.
96. Zhou Y, He C, Lin W, et al. (2017) Post-translational regulation of antiviral innate signaling. Eur
J Immunol 47: 1414–1426.
97. van Tol S, Hage A, Giraldo M, et al. (2017) The TRIMendous role of TRIMs in virus-host
interactions. Vaccines 5: 23.
98. Damgaard RB, Nachbur U, Yabal M, et al. (2012) The ubiquitin ligase XIAP recruits LUBAC for
NOD2 signaling in inflammation and innate immunity. Mol Cell 46: 746–758.
99. Keusekotten K, Elliott PR, Glockner L, et al. (2013) OTULIN antagonizes LUBAC signaling by
specifically hydrolyzing Met1-linked polyubiquitin. Cell 153: 1312–1326.
100. Rivkin E, Almeida SM, Ceccarelli DF, et al. (2013) The linear ubiquitin-specific deubiquitinase
gumby regulates angiogenesis. Nature 498: 318–324.
101. Takiuchi T, Nakagawa T, Tamiya H, et al. (2014) Suppression of LUBAC-mediated linear
ubiquitination by a specific interaction between LUBAC and the deubiquitinases CYLD and
OTULIN. Genes Cells 19: 254–272.

AIMS Allergy and Immunology

Volume 1, Issue 3, 143-163.

161

102. Tokunaga F, Nishimasu H, Ishitani R, et al. (2012) Specific recognition of linear polyubiquitin by
A20 zinc finger 7 is involved in NFκB regulation. Embo J 31: 3856–3870.
103. Hrdinka M, Fiil BK, Zucca M, et al. (2016) CYLD Limits Lys63- and Met1-Linked Ubiquitin at
receptor complexes to regulate innate immune signaling. Cell Rep 14: 2846–2858.
104. Damgaard RB, Walker JA, Marco-Casanova P, et al. (2016) The deubiquitinase OTULIN is an
essential negative regulator of inflammation and autoimmunity. Cell 166: 1215–1230.
105. Wang Q, Huang L, Hong Z, et al. (2017) The E3 ubiquitin ligase RNF185 facilitates the
cGAS-mediated innate immune response. Plos Pathog 13: e1006264.
106. Ni G, Konno H, Barber GN (2017) Ubiquitination of STING at lysine 224 controls IRF3
activation. Sci Immunol 2: In Press.
107. Zhang J, Hu MM, Wang YY, et al. (2012) TRIM32 protein modulates type I interferon induction
and cellular antiviral response by targeting MITA/STING protein for K63-linked ubiquitination. J
Biol Chem 287: 28646–28655.
108. Tsuchida T, Zou J, Saitoh T, et al. (2010) The ubiquitin ligase TRIM56 regulates innate immune
responses to intracellular double-stranded DNA. Immunity 33: 765–776.
109. Wang J, Yang S, Liu L, et al. (2017) HTLV-1 Tax impairs K63-linked ubiquitination of STING to
evade host innate immunity. Virus Res 232: 13–21.
110. Liu Y, Li J, Chen J, et al. (2015) Hepatitis B virus polymerase disrupts K63-linked ubiquitination
of STING to block innate cytosolic DNA-sensing pathways. J Virol 89: 2287–2300.
111. Zhong B, Zhang L, Lei C, et al. (2009) The ubiquitin ligase RNF5 regulates antiviral responses by
mediating degradation of the adaptor protein MITA. Immunity 30: 397–407.
112. Wang Y, Lian Q, Yang B, et al. (2015) TRIM30α is a negative-feedback regulator of the
intracellular DNA and DNA virus-triggered response by targeting STING. Plos Pathog 11:
e1005012.
113. Qin Y, Zhou MT, Hu MM, et al. (2014) RNF26 temporally regulates virus-triggered type I
interferon induction by two distinct mechanisms. Plos Pathog 10: e1004358.
114. Chen Y, Wang L, Jin J, et al. (2017) p38 inhibition provides anti-DNA virus immunity by
regulation of USP21 phosphorylation and STING activation. J Exp Med 214: 991–1010.
115. Lang X, Tang T, Jin T, et al. (2017) TRIM65-catalized ubiquitination is essential for
MDA5-mediated antiviral innate immunity. J Exp Med 214: 459–473.
116. Liu B, Zhang M, Chu H, et al. (2017) The ubiquitin E3 ligase TRIM31 promotes aggregation and
activation of the signaling adaptor MAVS through Lys63-linked polyubiquitination. Nat Immunol
18: 214–224.
117. Narayan K, Waggoner L, Pham ST, et al. (2014) TRIM13 is a negative regulator of
MDA5-mediated type I interferon production. J Virol 88: 10748–10757.
118. Gao D, Yang YK, Wang RP, et al. (2009) REUL is a novel E3 ubiquitin ligase and stimulator of
retinoic-acid-inducible gene-I. Plos One 4: e5760.
119. Oshiumi H, Matsumoto M, Hatakeyama S, et al. (2009) Riplet/RNF135, a RING-finger protein,
ubiquitinates RIG-I to promote interferon-beta induction during the early phase of viral infection.
J Biol Chem 284: 807–817.
120. Gack MU, Shin YC, Joo CH, et al. (2007) TRIM25 RING-finger E3 ubiquitin ligase is essential
for RIG-I-mediated antiviral activity. Nature 446: 916–920.
AIMS Allergy and Immunology

Volume 1, Issue 3, 143-163.

162

121. Jiang J, Li J, Fan W, et al. (2016) Robust Lys63-linked ubiquitination of RIG-I promotes cytokine
eruption in early influenza B virus infection. J Virol 90: 6263–6275.
122. Yan J, Li Q, Mao AP, et al. (2014) TRIM4 modulates type I interferon induction and cellular
antiviral response by targeting RIG-I for K63-linked ubiquitination. J Mol Cell Biol 6: 154–163.
123. Wang W, Jiang M, Liu S, et al. (2016) RNF122 suppresses antiviral type I interferon production
by targeting RIG-I CARDs to mediate RIG-I degradation. Proc Natl Acad Sci USA 113:
9581–9586.
124. Arimoto K, Takahashi H, Hishiki T, et al. (2007) Negative regulation of the RIG-I signaling by
the ubiquitin ligase RNF125. Proc Natl Acad Sci USA 104: 7500–7505.
125. Ning S, Campos AD, Darnay B, et al. (2008) TRAF6 and the three C-terminal lysine sites on
IRF7 are required for its ubiquitination-mediated activation by the tumor necrosis factor receptor
family member latent membrane protein 1. Mol Cell Biol 28: 6536–6546.
126. Ning S, Pagano J (2010) The A20 deubiquitinase activity negatively regulates LMP1 activation of
IRF7. J Virol 84: 6130–6138.
127. Iwai K, Fujita H, Sasaki Y (2014) Linear ubiquitin chains: NF-kappaB signalling, cell death and
beyond. Nat Rev Mol Cell Bio 15: 503–508.
128. Rieser E, Cordier SM, Walczak H (2013) Linear ubiquitination: a newly discovered regulator of
cell signalling. Trends Biochem Sci 38: 94–102.
129. Tokunaga F (2013) Linear ubiquitination-mediated NF-kappaB regulation and its related
disorders. J Biochem 154: 313–323.
130. Tokunaga F, Iwai K (2012) Linear ubiquitination: a novel NF-kappaB regulatory mechanism for
inflammatory and immune responses by the LUBAC ubiquitin ligase complex. Endocr J 59:
641–652.
131. Shimizu Y, Taraborrelli L, Walczak H (2015) Linear ubiquitination in immunity. Immunol Rev
266: 190–207.
132. Ikeda F (2015) Linear ubiquitination signals in adaptive immune responses. Immunol Rev 266:
222–236.
133. Ikeda F, Deribe YL, Skanland SS, et al. (2011) SHARPIN forms a linear ubiquitin ligase complex
regulating NF-kappaB activity and apoptosis. Nature 471: 637–641.
134. Tokunaga F, Nakagawa T, Nakahara M, et al. (2011) SHARPIN is a component of the
NF-kappaB-activating linear ubiquitin chain assembly complex. Nature 471: 633–636.
135. Tian Y, Zhang Y, Zhong B, et al. (2007) RBCK1 negatively regulates tumor necrosis factor- and
interleukin-1-triggered NF-kappaB activation by targeting TAB2/3 for degradation. J Biol Chem
282: 16776–16782.
136. Niu J, Shi Y, Iwai K, et al. (2011) LUBAC regulates NF-kappaB activation upon genotoxic stress
by promoting linear ubiquitination of NEMO. EMBO J 30: 3741–3753.
137. Hostager BS, Kashiwada M, Colgan JD, et al. (2011) HOIL-1L interacting protein (HOIP) is
essential for CD40 signaling. Plos One 6: e23061.
138. Zak DE, Schmitz F, Gold ES, et al. (2011) Systems analysis identifies an essential role for
SHANK-associated RH domain-interacting protein (SHARPIN) in macrophage Toll-like receptor
2 (TLR2) responses. Proc Natl Acad Sci USA 108: 11536–11541.

AIMS Allergy and Immunology

Volume 1, Issue 3, 143-163.

163

139. Rodgers MA, Bowman JW, Fujita H, et al. (2014) The linear ubiquitin assembly complex (LUBAC)
is essential for NLRP3 inflammasome activation. J Exp Med 211: 1333–1347.
140. Kirisako T, Kamei K, Murata S, et al. (2006) A ubiquitin ligase complex assembles linear
polyubiquitin chains. EMBO J 25: 4877–4887.
141. Emmerich CH, Schmukle AC, Walczak H (2011) The emerging role of linear ubiquitination in
cell signaling. Sci Signal 4: re5.
142. Tokunaga F, Sakata Si, Saeki Y, et al. (2009) Involvement of linear polyubiquitylation of NEMO
in NF-kappa B activation. Nat Cell Biol 11: 123–132.
143. Inn KS, Gack MU, Tokunaga F, et al. (2011) Linear ubiquitin assembly complex negatively
regulates RIG-I- and TRIM25-mediated type I interferon induction. Mol Cell 41: 354–365.
144. Zhang M, Tian Y, Wang RP, et al. (2008) Negative feedback regulation of cellular antiviral
signaling by RBCK1-mediated degradation of IRF3. Cell Res 18: 1096–1104.
145. Belgnaoui SM, Paz S, Samuel S, et al. (2012) Linear ubiquitination of NEMO negatively
regulates the interferon antiviral response through disruption of the MAVS-TRAF3 complex. Cell
Host Microbe 12: 211–222.
146. Wang L, Wang Y, Zhao J, et al. (2017) LUBAC modulates LMP1 activation of NFκB and IRF7. J
Virol 91: e1138–e1116.
147. Orzalli MH, DeLuca NA, Knipe DM (2012) Nuclear IFI16 induction of IRF-3 signaling during
herpesviral infection and degradation of IFI16 by the viral ICP0 protein. Proc Natl Acad Sci USA
109: E3008–E3017.
148. Li T, Chen J, Cristea IM (2013) Human cytomegalovirus tegument protein pUL83 inhibits
IFI16-mediated DNA sensing for immune evasion. Cell Host Microbe 14: 591–599.
149. Yu Y, Wang SE, Hayward GS (2005) The KSHV immediate-early transcription factor RTA
encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation.
Immunity 22: 59–70.
150. van Gent M, Braem SGE, de Jong A, et al. (2014) Epstein-Barr virus large tegument protein
BPLF1 contributes to innate immune evasion through interference with Toll-like receptor
signaling. Plos Pathog 10: e1003960.
151. Hu MM, Yang Q, Xie XQ, et al. (2016) Sumoylation promotes the stability of the DNA sensor
cGAS and the adaptor STING to regulate the kinetics of response to DNA virus. Immunity 45:
555–569.
152. Liang Q, Deng H, Li X, et al. (2011) Tripartite motif-containing protein 28 is a small
ubiquitin-related modifier E3 ligase and negative regulator of IFN Regulatory Factor 7. J
Immunol 187: 4754–4763.
153. Yang WL, Zhang X, Lin HK (2010) Emerging role of Lys-63 ubiquitination in protein kinase and
phosphatase activation and cancer development. Oncogene 29: 4493–4503.
154. Yang Y, Kelly P, Schmitz R, et al. (2016) Targeting non-proteolytic protein ubiquitination for the
treatment of diffuse large B cell lymphoma. Cancer Cell 29: 494–507.
© 2017 Shunbin Ning, et al., licensee AIMS Press. This is an open
access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0)
AIMS Allergy and Immunology

Volume 1, Issue 3, 143-163.

